×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
PR Newswire
PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has been completed in the...
12 hours ago
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Citizen Tribune
Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024.
10 hours ago
Market Sentiment Around Loss-Making Lipocine Inc. (NASDAQ:LPCN)
Yahoo Movies UK
We feel now is a pretty good time to analyse Lipocine Inc.'s ( NASDAQ:LPCN ) business as it appears the company may be...
3 days ago
Lipocine Initiates New ATM Offering, Ends Previous Agreement - TipRanks.com
Tipranks
Lipocine (LPCN) has shared an update. Lipocine Inc. has entered into a new at-the-market (ATM) agreement with A.G.P./Alliance Global...
5 days ago
Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs
Clinical Trials Arena
CEO of Lipocine, Dr Mahesh Patel said the company will be meeting with the FDA to discuss future plans for LPCN 2401.
3 weeks ago
Lipocine (NASDAQ:LPCN) Receives New Coverage from Analysts at StockNews.com
Defense World
Read Lipocine (NASDAQ:LPCN) Receives New Coverage from Analysts at StockNews.com at Defense World.
4 days ago
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
PR Newswire
(NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that commercialization...
2 months ago
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ...
Yahoo Finance
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced results from a Phase 2 clinical trial (NCT04134091) which...
3 weeks ago
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
PR Newswire
Lipocine reported a net loss of $16.4 million, or ($3.14) per diluted share, for the year ended December 31, 2023, compared with a net loss of...
1 month ago
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
PR Newswire
Mahesh Patel, President and CEO of Lipocine. "LPCN 1154 is targeted to be a highly effective, oral, fast-acting and short duration treatment...
2 months ago